Dicer suppression inhibits thyroid cancer cell proliferation and induces p21-mediated senescence
Background
The role of Dicer, a key enzyme in micro (mi)RNA biosynthesis, in driving thyroid carcinogenesis has been largely unknown. Well-differentiated thyroid carcinoma (WDTC), including papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), represents a significant clinical challenge, with current treatments often focusing on surgical intervention and radioiodine therapy. Understanding novel molecular pathways, such as those involving Dicer, could uncover new therapeutic targets to improve patient outcomes and address gaps in current treatment strategies.
Study Design
Researchers investigated Dicer's role in WDTC by first measuring Dicer messenger (m)RNA and protein levels in thyroid cancer complementary (c)DNA and tissue arrays. Subsequently, they applied silencing of Dicer1 in papillary thyroid cancer (TPC-1), follicular thyroid cancer (FTC), and normal thyroid (Nthy-ori 3-1) cell lines. The study evaluated effects on tumor behaviors, including cell proliferation, cell-cycle progression, and expression of key senescence markers. Assays included qPCR for mRNA, immunohistochemistry for protein, bromodeoxyuridine (BrdU) incorporation for DNA synthesis, and flow cytometry for cell cycle analysis.
Results
Dicer1 mRNA was found to be upregulated in PTC tissues, while the Dicer protein was overexpressed in PTC and FTC tissues. Suppressing Dicer led to significant inhibition of cell proliferation in all cell lines tested, and repression of cell-cycle progression signatures specifically in TPC-1 cells. Furthermore, p21 expression consistently increased in response to compromising Dicer in all four cell lines (TPC-1, FTC, and Nthy-ori 3-1, plus an unspecified fourth, likely a control or another variant).
Key Findings
- Dicer1 mRNA was upregulated in papillary thyroid cancer (PTC) tissues.
- Dicer protein was overexpressed in PTC and follicular thyroid cancer (FTC) tissues.
- Suppressing Dicer inhibited cell proliferation in all tested cell lines.
- Dicer repression consistently increased
p21expression in all four cell lines. - Dicer1-knockdown cells showed nuclear
phospho-H2AXstaining, reducedBrdUincorporation, and G1 phase arrest.
Why It Matters
This study identifies Dicer as a potential therapeutic target for well-differentiated thyroid carcinoma. By demonstrating that Dicer suppression inhibits proliferation and induces senescence, it suggests a novel strategy for controlling thyroid cancer growth. Targeting Dicer could offer a mechanism to induce cell cycle arrest and cellular senescence in thyroid cancer cells, potentially complementing existing therapies. While this is an in-vitro study, the findings lay groundwork for future preclinical animal models and eventually, human clinical trials, moving towards a usable protocol for Dicer modulation in cancer therapy.
dicer
thyroid-cancer
cell-proliferation
senescence
p21
in-vitro